November 12th 2024
The initiation of a phase 2 study of the investigational 31-valent pneumococcal conjugate vaccine is expected by the end of January 2025.
Meeting to discuss COVID-19 vaccine in kids 6 months to 4 years postponed
February 11th 2022The US Food and Drug Administration announces that the meeting to discuss extending the emergency use authorization for the Pfizer/BioNTech vaccine to children aged 6 months to 4 years has been postponed until data on a third dose has been studied.
COVID-19 vaccine exposure in utero not linked to adverse neonatal outcomes
February 11th 2022The safety of the Pfizer/BioNTech COVID-19 vaccine in pregnant women, for both mother and baby, has been dependent on observation during the rollout. A large population trial provides further support for the vaccine’s safety.
Does maternal history of cervical cancer/biopsy impact HPV vaccine rate in kids?
December 16th 2021For mothers who have an experience with human papillomavirus (HPV) vaccine preventable outcomes such as a cervical biopsy or cancer, would this history make them more likely to have their child receive this vaccine? It may seem likely, but a new study raises questions about this belief.
Trial examines safety and efficacy of HPV vaccine in young cancer survivors
November 22nd 2021Surviving a bout of cancer early in life puts children and teenagers at risk of cancers linked to human papillomavirus (HPV). A phase 2 trial examined how effective a 3-dose series was in providing protection.